Silence Therapeutics plc ADR (SLN)
Silence Therapeutics (SLN) Loses 28.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Silence Therapeutics (SLN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
Silence Therapeutics (SLN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Silence Therapeutics plc (SLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in Silence Therapeutics (SLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Silence Therapeutics' Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
Silence Therapeutics NASDAQ: SLN reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its primary endpoint and supporting the company's plan to advance a quarterly dosing regimen into Phase III.
SLN Stock Skyrockets 107% in Six Months: Here's What You Need to Know
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.
Silence Therapeutics (SLN) Moves 7.2% Higher: Will This Strength Last?
Silence Therapeutics (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Silence Therapeutics: PV Data Could Wake The Stock (Initiating Buy)
I initiate Silence Therapeutics at a speculative Buy, driven by near-term divesiran/SLN124 catalysts in polycythemia vera (PV). SLN's mRNAi GOLD GalNAc-siRNA platform enables infrequent dosing and strong target knockdown, potentially differentiating divesiran from weekly competitors like Rusfertide. Phase 1 SANRECO data show promising phlebotomy reduction and symptom improvement, but safety and efficacy require confirmation in the pivotal Phase 2 readout (August 2026).
Silence Therapeutics (SLN) Surges 26.0%: Is This an Indication of Further Gains?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?
The consensus price target hints at a 467.5% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Silence Therapeutics: Divesiran Targets High-Burden PV
Silence Therapeutics is advancing its lead RNAi drug, divesiran, for polycythemia vera, with a fully enrolled Phase 2 trial and results expected in Q3 2026. SLN boasts a strong cash position ($100M+), providing runway through 2028 and enabling continued pipeline development without near-term financing risks. The SANRECO trial's design and patient population position divesiran as a potential adjunctive therapy for high-burden PV patients, focusing on reduced phlebotomy frequency and infrequent dosing.
